Sumitomo Dainippon Enters Neurology Partnership with Otsuka Pharmaceuticals for US$890 M
By Swati Sharan
Pharma Deals Review: Vol 2022 Issue 1 (Table of Contents)
Published: 8 Jan-2022
DOI: 10.3833/pdr.v2022.i1.2653 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to broaden its neurology franchise, Sunovion Pharmaceuticals, a subsidiary of Sumitomo Dainippon has entered into a global collaboration and license agreement with Otsuka Pharmaceuticals to develop and commercialise four psychiatry and neurology compounds...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS